Corcept Therapeutics Incorporated (LON:0I3Q)

Market Cap	5.84B -0.8%
Revenue (ttm)	725.85M +30.0%
Net Income	120.04M +52.9%
EPS	0.99 +52.2%
Shares Out	n/a
PE Ratio	54.29
Forward PE	11.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155
Open	75.51
Previous Close	75.54
Day's Range	72.17 - 76.27
52-Week Range	28.67 - 126.57
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 3, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 730
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0I3Q

Financial Performance

In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error